Stem Cell Therapeutics Corp. Expands Executive Team by Appointing Thomas Franck as Vice President of Commercial Planning
30 May 2008 - 9:30PM
Marketwired
CALGARY, ALBERTA (TSX VENTURE: SSS) is pleased to announce the
appointment of Mr. Thomas Franck as Vice President of Commercial
Planning.
Mr. Thomas R. Franck is a 30-year veteran of Procter &
Gamble. He has pharmaceutical sales and marketing experience in the
U.S., Canada, Latin America and Europe. He also has consumer
marketing experience in the U.S. and Canada. For the last 10 years
of his career at Procter & Gamble, he was in new products
marketing for pharmaceuticals; and for the remaining 5 years he was
Marketing Director (Department Head), Pharmaceuticals Research
& Licensing & Acquisitions Planning Department with global
responsibility for the market and financial assessment of both
internal and external new drug product opportunities.
After Procter & Gamble, Mr. Franck became founder and
Principal of Amelia Island Consulting (AIC) which is a health care
consulting service that provides target market profiling,
competitive analysis and estimates of global value for
pharmaceuticals and medical devices. AIC specializes in early stage
research and development projects and can aid in portfolio
management and pre-launch professional relations. He has completed
projects for several biotechnology companies.
Dr. Alan Moore, President and CEO of SCT commented as
follows:
"We are very excited to add Mr. Thomas Franck to the SCT
executive team given his extensive experience and skill as a sales
and marketing manager. His current focus on development projects
will play a key role with SCT's pre-Phase III planning. Mr.
Franck's knowledge will assist in managing our pre-launch
professional relations. He will also help to establish the
valuation both of invidiual programs and the Company as a whole.
This is an important time for SCT as we prepare for the commercial
development of our stroke program."
SCT has issued 250,000 stock options to Mr. Franck at an
exercise price of C$0.26 per share in connection with his
appointment to the Executive team. These options will expire no
later than May 26, 2013 subject to applicable vesting provisions.
These options were awarded in accordance with the Corporations
Stock Option Plan.
About NTx(TM)-265: NTx(TM)-265 is a therapeutic regimen of two
approved and clinically well-defined drugs, human Chorionic
Gonadotropin (hCG) and Erythropoietin (EPO), targeting the
treatment of stroke. The twin objectives of the regimen are to
stimulate the growth and differentiation of new neurons to replace
the brain cells that were lost or damaged by the stroke, and
importantly, to direct motor, visual and cognitive recovery after
acute ischemic stroke. Animal studies have shown a significant
recovery in motor function after receiving the NTx(TM)-265 regimen
24-48 hours post stroke. Encouraging clinical results in SCT's
BETAS Phase IIa stroke trial were presented at the International
Stroke Conference in February 2008, showing clinically relevant
recovery in 8 of 8 patients who received the complete regimen. SCT
is recruiting patients for the multi-centre, double-blind,
placebo-controlled REGENESIS Phase IIb stroke study for NTx(TM)-265
with primary endpoints of efficacy. Patient enrollment is expected
to be complete by the end of 2008 with top-line efficacy data
expected to be released before the end of the first quarter of
2009.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a Canadian public biotechnology company (TSX-V: SSS) focused on
the development and commercialization of drug-based therapies to
treat central nervous system diseases. SCT is a leader in the
development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The company's programs aim to
repair neurological function lost due to disease or injury. The
company's extensive patent portfolio of owned and licensed
intellectual property supports the potential expansion into future
clinical programs in numerous neurological diseases such as
traumatic brain injury and multiple sclerosis.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 Email: amoore@stemcellthera.com Stem
Cell Therapeutics Corp. Chloe Douglas-Crampton Investor Relations
(403) 245-5495 ext. 221 Email: crampton@stemcellthera.com Website:
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Nov 2023 to Nov 2024
